UTMD Files 8-K on Operations & Financial Condition

TL;DR

**UTMD just dropped an 8-K with fresh financial results, time to check their numbers!**

AI Summary

Utah Medical Products, Inc. filed an 8-K on January 30, 2024, to report on its results of operations and financial condition, as well as to include financial statements and exhibits. This filing, under SEC File Number 001-12575, indicates that the company is providing updated financial information. For investors, this matters because it signals that new financial data is available, which could influence their perception of the company's performance and future prospects, potentially affecting stock price.

Why It Matters

This filing provides investors with updated financial information, which is crucial for evaluating the company's current health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently indicate a high level of risk.

Analyst Insight

A smart investor would review the detailed financial statements and results of operations once they become available to assess the company's performance and financial health, as this 8-K signals their imminent release.

Key Numbers

• 2024-01-30 — Filing Date (The date the 8-K was filed with the SEC.)
• 001-12575 — SEC File Number (Unique identifier for Utah Medical Products, Inc.'s filings with the SEC.)
• 801-566-1200 — Business Phone (Contact number for Utah Medical Products, Inc.)

Key Players & Entities

• Utah Medical Products, Inc. (company) — the registrant filing the 8-K
• January 30, 2024 (date) — date of earliest event reported and filing date
• 001-12575 (dollar_amount) — SEC File Number for Utah Medical Products, Inc.
• 7043 South 300 West, Midvale, Utah, 84047 (company) — principal executive offices address
• 801-566-1200 (dollar_amount) — registrant's telephone number

FAQ

Filing Documents

• utmd-20240130.htm (8-K) — 25KB
• utmd_ex99z1.htm (EX-99.1) — 103KB
• 0001096906-24-000127.txt ( ) — 270KB
• utmd-20240130_def.xml (EX-101.DEF) — 2KB
• utmd-20240130_lab.xml (EX-101.LAB) — 20KB
• utmd-20240130_pre.xml (EX-101.PRE) — 13KB
• utmd-20240130.xsd (EX-101.SCH) — 2KB
• utmd-20240130_htm.xml (XML) — 2KB

02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02—RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three and twelve months ended December 31, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated January 30, 2024. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

01—FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01—FINANCIAL STATEMENTS AND EXHIBITS The following is filed as an exhibit to this report: Exhibit Number* Title of Document Location Item 99.1 Financial information for Utah Medical Prod ucts, Inc. for the three and twelve months ended December 31 , 2023 and forward-looking statements relating to 2023 and beyond as present ed in a press release dated January 30, 2024 . This filing _______________________________________ * All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UTAH MEDICAL PRODUCTS, INC. Dated: January 30, 2024 By: /s/ Kevin L. Cornwell Kevin L. Cornwell, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR